Clinical Trial Update: Cardiovascular Risk Stratification of Ambulatory Patients in Primary Prevention

View source ↗

Summary

AstraZeneca-sponsored study on cardiovascular risk stratification in ambulatory patients for primary prevention has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Snippet

Sponsor: AstraZeneca | Conditions: Cardiovascular Primary Prevention | Status: COMPLETED